Blencowe Resources plc (LON:BRES) CEO Mike Ralston talks though the April 2020 Orom-Cross jumbo graphite project presentation. Blencowe Resources is developing the Orom-Cross jumbo flake graphite project uganda. Orom-Cross is a
Amino Technologies plc (LON:AMO) Investor Presentation Highlights Year End Nov 2019 presented by Group CEO Donald McGarva. Amino Technologies is a new breed of Media Tech business, focused on enabling operators
KRM22 plc (LON:KRM) Chairman Keith Todd talks though the new March 2020 investor presentation. KRM22 is a closed-ended investment company which listed on AIM on 30 April 2018. The Company has
Open Orphan plc (LON:ORPH) Co-Founder and Executive Chairman Cathal Friel talks us though the Feb 2020 Investor Presentation. Open Orphan was founded in 2017, with the goal of rapidly building Europe’s
Manolete Partners (LON:MANO), the leading UK-listed insolvency litigation financing company, has published its latest investor presentation. Manolete Partners Plc operates as an insolvency litigation financing company in the United Kingdom. The
KEFI Minerals plc (LON:KEFI) is an exploration and development company focussed on gold and copper deposits, primarily in the highly prospective Arabian-Nubian Shield.
Union Jack Investment Summary • Low-risk onshore strategy focused on drill-ready projects and value creation • Balanced portfolio: production, development, appraisal and exploration • Portfolio activity generates near-term news flow
Jubilee Metals Group PLC (LON:JLP),the AIM and Altx traded metals processing company, today announced that the Company’s new corporate presentation can be viewed on its website at http://bit.ly/2lUgIFH Jubilee Metals Group
Microsaic Systems (LON:MSYS) Investor Presentation by Glenn Tracey. Microsaic Systems plc is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry (“MS”) instruments that are designed to improve
Avacta plc (LON: AVCT) Affimer Innovative Immunotherapies Presentation Feb 2019 by CEO Alastair Smith. Avacta’s principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
